Sucralose as co-crystal co-former for hydrochlorothiazide: development of oral disintegrating tablets.

Drug Dev Ind Pharm

a Department of Pharmaceutical Technology, College of Pharmacy , University of Tanta, Tanta , Egypt.

Published: August 2016

Development of oral disintegrating tablets requires enhancement of drug dissolution and selection of sweetener. Co-crystallization of drugs with inert co-former is an emerging technique for enhancing dissolution rate. The benefit of this technique will become even greater if one of the sweeteners can act as co-crystal co-former to enhance dissolution and mask the taste. Accordingly, the objective of this work was to investigate the efficacy of sucralose as a potential co-crystal co-former for enhancing the dissolution rate of hydrochlorothiazide. This was extended to prepare oral disintegrating tablets. Co-crystallization was achieved after dissolving hydrochlorothiazide with increasing molar ratios of sucralose in the least amount of acetone. The co-crystallization products were characterized using Fourier transform infrared spectroscopy, differential thermal analysis and powder X-ray diffraction. These measurements indicated that co-crystallization process started at a drug sucralose molar ratio of 1:1 and completed at 1:2. The developed co-crystals exhibited faster drug dissolution compared with the control, with co-crystal containing the drug with sucralose at 1:2 molar ratio being optimum. The later was used to prepare fast disintegrating tablets. These tablets had acceptable physical characteristics and showed fast disintegration with subsequent rapid dissolution. The study introduced sucralose as co-crystal co-former for enhanced dissolution and masking the taste.

Download full-text PDF

Source
http://dx.doi.org/10.3109/03639045.2015.1118495DOI Listing

Publication Analysis

Top Keywords

co-crystal co-former
16
disintegrating tablets
16
oral disintegrating
12
sucralose co-crystal
8
development oral
8
drug dissolution
8
enhancing dissolution
8
dissolution rate
8
drug sucralose
8
sucralose molar
8

Similar Publications

Insights into pharmaceutical co-crystallization using coherent Raman microscopy.

J Pharm Sci

January 2025

Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland. Electronic address:

Article Synopsis
  • This study focuses on the process of creating co-crystals of active pharmaceutical ingredients (APIs) and highlights the importance of understanding co-crystallization behaviors under different conditions.
  • The researchers utilized two advanced imaging techniques, narrowband CARS and hyperspectral SRS, to observe co-crystallization in real-time, revealing key differences in component identification and overall co-crystal formation.
  • The findings provide new insights into the co-crystallization process, including unexpected trace forms and the influence of ethanol content on co-crystal stability during milling.
View Article and Find Full Text PDF

Biochanin-A co-crystal formulation improves bioavailability and ameliorates cerulein-induced pancreatitis by attenuating the inflammation.

Int J Pharm

December 2024

Department of Applied Biology, CSIR-Indian Institute of Chemical Technology, Hyderabad 500 007, Telangana, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, Uttar Pradesh 201 002, India. Electronic address:

Co-crystallization of a therapeutic ingredient with an appropriate co-former is a powerful technique to augment the physicochemical and pharmacokinetic properties and the effectiveness of Active Pharmaceutical Ingredients (APIs). Biochanin A (BCA), a flavonoid with medicinal potential, is limited by poor solubility and low oral bioavailability. This study aimed to design and develop a novel BCA-nicotinamide cocrystal as BCC to enhance BCA's oral bioavailability and explore its therapeutic potential for ameliorating cerulein-induced acute pancreatitis (CIAP) by elucidating the target identification utilizing tissue/serum metabolite profiles.

View Article and Find Full Text PDF

Flavonoids are polyphenolic compounds that have multiple benefits in treating various life-threatening diseases. Despite their diverse pharmacological activities, the market potential of flavonoids is hampered due to their poor solubility and low bioavailability after oral administration. The current review highlights the role of co-crystals and co-amorphous systems (CAMs) in enhancing the solubility, permeability, bioavailability, and therapeutic efficacy of flavonoids.

View Article and Find Full Text PDF

The objective of this review is, to discuss recent advancements in screening methods for co-formers, evaluation cum confirmation methods and co-crystallization with examples. Co-crystals are considered as a new form of an old drug entity. Co-crystals improve the stability, hygroscopicity, solubility, dissolution, and physicochemical properties of pure drugs without altering chemical and pharmacological properties.

View Article and Find Full Text PDF

Co-Processed Crystalline Solids of Ivermectin with Span 60 as Solubility Enhancers of Ivermectin in Natural Oils.

AAPS PharmSciTech

March 2024

Centre of Excellence for Pharmaceutical Sciences (Pharmacen™), North-West University, Private Bag X6001, Potchefstroom, 2520, South Africa.

Despite being discovered over five decades ago, little is still known about ivermectin. Ivermectin has several physico-chemical properties that can result in it having poor bioavailability. In this study, polymorphic and co-crystal screening was used to see if such solid-state modifications can improve the oil solubility of ivermectin.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!